Skip to main content
SanofiIn development

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

Source: Autobound Signal API · 81 signals tracked for Sanofi · updated

Get Sanofi's live signals in Claude or ChatGPT, or by API

AskWhat changed at Sanofi this week? Use Autobound signals for sanofi.com.

What happened

Sanofi initiated a Phase 3 clinical trial in Europe evaluating an influenza-COVID-19 combination vaccine utilizing Novavax's Nuvaxovid and Sanofi's Efluelda/Fluzone High-Dose.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax (Nasdaq: NVAX ) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™. Sanofi's Phase 3 trial, being conducted in Europe, is assessing the safety and immunogenicity of Nuvaxovid in combination with Sanofi's marketed Efluelda/Fluzone ® High-Dose vaccine in adults aged 60 and older. "Novavax and Sanofi continue to successfully execute on the opportunities afforded by our partnership. To date, the partnership has generated over $1 billion in revenue for Novavax," 2 said John C. Jacobs, President and Chief Executive Officer, Novavax. "Sanofi has stated that they intend to be one of the first movers in the combination vaccine segment, and Novavax believes this is an important step toward that goal. We are excited about the value we are building together with our partners." Under the collaboration and license agreement, for Nuvaxovid, Novavax is eligible to receive royalties on Sanofi sales and a $75 million milestone payment upon the successful completion of the manufacturing technology transfer anticipated in mid-2027. Novavax is also eligible to receive an additional milestone of $225 million upon a U.S. launch of an influenza-COVID-19 combination vaccine following successful...

Keep reading with a free account

The rest of this article, and every signal for Sanofi, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
influenza-COVID-19 combination vaccine

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Oct 29, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Sanofi and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Sanofi this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/349a3e02-ee01-3867-2427-7d50059d7a6d returns this record as JSON. POST /v1/companies/enrich returns every signal for sanofi.com.

{
  "signal_id": "349a3e02-ee01-3867-2427-7d50059d7a6d",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-29T13:37:00+00:00",
  "company": {
    "name": "Sanofi",
    "domain": "sanofi.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/novavax-earns-125-million-milestone-as-sanofi-launches-phase-3-influenza-covid-19-combination-vaccine-trial-in-europe-302923786.html",
    "title": "Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe",
    "excerpt": "GAITHERSBURG, Md. , Oct. 29, 2026 /PRNewswire/ -- Novavax (Nasdaq: NVAX ) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™. Sanofi's Phase 3 trial, being conducted in Europe, is assessing the safety and immunogenicity of Nuvaxovid in combination with Sanofi's marketed Efluelda/Fluzone ® High-Dose vaccine in adults aged 60 and older. \"Novavax and Sanofi continue to successfully execute on the opportunities afforded by our partnership. To date, the partnership has generated over $1 billion in revenue for Novavax,\" 2 said John C. Jacobs, President and Chief Executive Officer, Novavax. \"Sanofi has stated that they intend to be one of the first movers in the combination vaccine segment, and Novavax believes this is an important step toward that goal. We are excited about the value we are building together with our partners.\" Under the collaboration and license agreement, for Nuvaxovid, Novavax is eligible to receive royalties on Sanofi sales and a $75 million milestone payment upon the successful completion of the manufacturing technology transfer anticipated in mid-2027. Novavax is also eligible to receive an additional milestone of $225 million upon a U.S. launch of an influenza-COVID-19 combination vaccine following successful...",
    "product": "influenza-COVID-19 combination vaccine",
    "summary": "Sanofi initiated a Phase 3 clinical trial in Europe evaluating an influenza-COVID-19 combination vaccine utilizing Novavax's Nuvaxovid and Sanofi's Efluelda/Fluzone High-Dose.",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS1075465/Novavax-Logo.jpg?id=OA3047412&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "influenza-COVID-19 combination vaccine",
      "full_text": "influenza-COVID-19 combination vaccine",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-29T13:37:00Z",
    "article_sentence": "Sanofi's Phase 3 trial, being conducted in Europe, is assessing the safety and immunogenicity of Nuvaxovid in combination with Sanofi's marketed Efluelda/Fluzone ® High-Dose vaccine in adults aged 60 and older."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.